Optimising clinical trial design for proof of neuroprotection in acute ischaemic stroke: The SAINT clinical trial programme

Cerebrovascular Diseases

Volumn 22, Issue SUPPL. 1, 2006, Pages 18-24

  Davis, Stephen ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Acute ischaemic stroke; Clinical trial programme; Neuroprotection; NXY 059; Stroke Acute Ischaemic NXY 059 Treatment (SAINT); Stroke Therapy Academic Industry Roundtable (STAIR)

Indexed keywords

3 (5 CHLORO 2 METHOXYPHENYL) 3 FLUORO 2,3 DIHYDRO 6 TRIFLUOROMETHYL 1H INDOL 2 ONE; 4 PHOSPHONOMETHYLPIPECOLIC ACID; ALTEPLASE; ANTIINFLAMMATORY AGENT; APTIGANEL; ARUNDIC ACID; CLOMETHIAZOLE; DISUFENTON SODIUM; ELIPRODIL; FOSPHENYTOIN SODIUM; FREE RADICAL; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; LUBELUZOLE; NEUROPROTECTIVE AGENT; NEUTROPHIL INHIBITORY FACTOR; NIMODIPINE; RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR; REPINOTAN; SCAVENGER; TIRILAZAD; UK 279276; UNCLASSIFIED DRUG;

ACUTE DISEASE; ADVERSE DRUG REACTION; BRAIN FUNCTION; BRAIN INFARCTION SIZE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE MODEL; DRUG ABUSE; DRUG EFFECT; DRUG EFFICACY; DRUG TREATMENT FAILURE; EVALUATION; HUMAN; METHODOLOGY; NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; SAMPLE SIZE; SYMPTOM; TIME;

EID: 33646551189     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000092329     Document Type: Conference Paper

References (45)

1. Stroke Unit Trialists' Collaboration: How do stroke units improve patient outcomes? A collaborative systematic review of the randomized trials. Stroke 1997;28:2139-2144.
2. Stroke Unit Trialists' Collaboration: Collaborative systematic review of the randomised trials of organised inpatient (stroke unit) care after stroke. BMJ 1997;314:1151-1159.
3. CAST (Chinese Acute Stroke Trial) Collaborative Group: CAST: randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke. Lancet 1997;349:1641-1649.
4. International Stroke Trial Collaborative Group: The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke. Lancet 1997;349:1569-1581.
5. Chen ZM, Sandercock P, Pan HC, Counsell C, Collins R, Liu LS, Xie JX, Warlow C, Peto R, on behalf of the CAST and IST collaborative groups: Indications for early aspirin use in acute ischemic stroke. A combined analysis of 40 000 randomized patients from the Chinese acute stroke trial and the international stroke trial. Stroke 2000;31:1240-1249.
6. NINDS rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581-1587.
7. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, Silver F, Rivera F, for the PROACT investigators: Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. JAMA 1999;282:2003-2011.
8. Sherman DG, Atkinson RP, Chippendale T, Levin KA, Ng K, Futrell N, Hsu CY, Levy DE, for the STAT Participants: Intravenous ancrod for treatment of acute ischemic stroke. The STAT study: a randomized controlled trial. JAMA 2000;283:2395-2403.
9. Abciximab Emergent Stroke Treatment Trial (AbESTT) Investigators: Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized phase 2 trial. Stroke 2005;36:880-890.
10. Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, Fischer M, Furlan A, Kaste M, Lees KR, Soehngen M, Warach S, for the DIAS Study Group: The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005;36:66-73.
11. Felten RP, Ogden NR, Pena C, Provost MC, Schlosser MJ, Witten CM: The Food and Drug Administration medical device review process: clearance of a clot retriever for use in ischemic stroke. Stroke 2005;36:404-406.
12. Kidwell CS, Liebeskind DS, Starkman S, Saver JL: Trends in acute ischemic stroke trials through the 20th century. Stroke 2001;32:1349-1359.
13. Fisher M, for the Stroke Therapy Academic Industry Roundtable: Recommendations for advancing development of acute stroke therapies. Stroke Therapy Academic Industry Roundtable 3. Stroke 2003;34:1539-1546.
14. Stroke Therapy Academic Industry Roundtable (STAIR): Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999;30:2752-2758.
15. Stroke Therapy Academic Industry Roundtable II (STAIR-II): Recommendations for clinical trial evaluation of acute stroke therapies. Stroke 2001;32:1598-1606.
16. Fisher M, Albers GW, Donnan GA, Furlan AJ, Grotta JC, Kidwell CS, Sacco RL, Wechsler LR: Enhancing the development and approval of acute stroke therapies: Stroke Therapy Academic Industry Roundtable. Stroke 2005;36:1808-1813.
17. Dirnagl U, Iadecola C, Moskowitz MA: Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 1999;22:391-397.
18. Fisher M: The ischemic penumbra: identification, evolution and treatment concepts. Cerebrovasc Dis 2004;17(suppl 1):1-6.
19. Beresford IJM, Parsons AA, Hunter AJ: Treatments for stroke. Expert Opin Emerging Drugs 2003;8:103-122.
20. Fisher M, Schaebitz W: An overview of acute stroke therapy. Past, present, and future. Arch Intern Med 2000;160:3196-3206.
21. Bayer Global. 2005. (Accessed April, 2005, at Bayer Global).
22. ONO Pharmaceutical Co Ltd. 2005. (Accessed May, 2005, at ONO Pharmaceutical Co Ltd).
23. Fisher M, Brott TG: Emerging therapies for acute ischemic stroke. New therapies on trial. Stroke 2003;34:359-361.
24. Yam PS, Patterson J, Graham DI, Takasago T, Dewar D, McCulloch J: Topographical and quantitative assessment of white matter injury following a focal ischaemic lesion in the rat brain. Brain Res Brain Res Protoc 1998;2:315-322.
25. Davis SM, Donnan GA: Neuroprotection: establishing proof of concept in human stroke. Stroke 2002;33:309-310.
26. Samsa GP, Matchar DB: Have randomized controlled trials of neuroprotective drugs been underpowered? An illustration of three statistical principles. Stroke 2001;32:669-674.
27. Heiss WD, Thiel A, Grond M, Graf R: Which targets are relevant for therapy of acute ischemic stroke? Stroke 1999;30:1486-1489.
28. Cheng YD, Al-Khoury L, Zivin JA: Neuroprotection for ischemic stroke: two decades of success and failure. Neurorx 2004;1:36-45.
29. Davis SM, Lees KR, Albers GW, Diener HC, Markabi S, Karlsson M, Norris J: Selfotel in acute ischemic stroke: possible neurotoxic effects of an NMDA antagonist. Stroke 2000;31:347-354.
30. Ovbiagele B, Kidwell CS, Starkman S, Saver JL: Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep 2003;3:9-20.
31. Green AR, Odergren T, Ashwood T: Animal models of stroke: do they have value for discovering neuroprotective agents? Trends Pharmacol Sci 2003;24:402-408.
32. Wahlgren NG, Ahmed N.Neuroprotection in cerebral ischaemia: facts and fancies - the need for new approaches. Cerebrovasc Dis 2004;17(suppl 1):153.
33. Kuroda S, Tsuchidate R, Smith ML, Maples KR, Siesjö BK: Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat. J Cereb Blood Flow Metab 1999;19:778-787.
34. Sydserff SG, Borelli AR, Green AR, Cross AJ: Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window. Br J Pharmacol 2002;135:103-112.
35. Zhao Z, Cheng M, Maples KR, Ma JY, Buchan AM: NXY-059, a novel free radical trapping compound, reduces cortical infarction after permanent focal cerebral ischemia in the rat. Brain Res 2001;909:46-50.
36. Marshall JWB, Cummings RM, Bowes LJ, Ridley RM, Green AR: Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4 hours after occlusion. Stroke 2003;34:2228-2233.
37. Lees KR, Sharma AK, Barer D, Ford GA, Kostulas V, Cheng Y-F, Odergren T, for the SA-NXY-0003 Investigators: Tolerability and pharmacokinetics of the nitrone NXY-059 in patients with acute stroke. Stroke 2001;32:675-680.
38. Lees KR, Barer D, Ford GA, Hacke W, Kostulas V, Sharma AK, Odergren T, for the SA-NXY-0004 Investigators: Tolerability of NXY-059 at higher target concentrations in patients with acute stroke. Stroke 2003;34:482-487.
39. Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener HC, Grotta J, Lyden P, Shuaib A, Hardemark HG, Wasiewski WW: NXY-059 for acute ischemic stroke. N Engl J Med 2006;354:588-600.
40. Diener HC, Davalos A, Davies SM, Grotta J, Lees KR, Lyden P, Shuaib A, Zivin JA, Ashwood T, Wasiewski W, for the SAINT I Trial Investigators: SAINT I: A double-blind, multicentre, placebo-controlled study to assess the efficacy and safety of NXY-059 in acute ischaemic stroke. Eur J Neurol 2005, in press.
41. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, Van Gijn J: Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19:604-607.
42. Brott T, Adams HP, Jr., Olinger CP, Marler JR, Barsan WG, Biller J, Spilker J, Holleran R, Eberle R, Hertzberg V: Measurements of acute cerebral infarction: a clinical examination scale. Stroke 1989;20:864-870.
43. Mahoney FI, Barthel DW: Functional evaluation: the Barthel Index. Md State Med J 1965;14:61-65.
44. Duncan PW, Wallace D, Studenski S, Lai SM, Johnson D: Conceptualization of a new stroke-specific outcome measure: the stroke impact scale. Top Stroke Rehabil 2001;8:19-33.
45. Rabin R, de Charro F: EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001;33:337-343.